Annals of Oncology 15:139-145, 2004
© 2004 European Society for Medical Oncology
Original Paper |
Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients
Received 10 June 2003; revised 12 August 2003; accepted 28 August 2003Background:
There is accumulating evidence from preclinical studies that circulating endothelial cells (CECs) play an important role in neovascularization and tumor growth. The role of CECs in human cancer progression is sparsely investigated. We therefore analyzed CECs in peripheral blood of cancer patients. In addition, we correlated CEC levels in these patients with plasma levels of cytokines that are known to mobilize CECs in experimental models.
Patients and methods:
Viable CECs were isolated, quantified and cultured from cancer patients’ whole blood by using magnetic beads coupled to an antibody directed against CD146, a pan-endothelial marker. Viable cells were visualized by calceinAM staining. Positive staining for specific endothelial cell markers [i.e. von Willebrand factor, CD31, vascular endothelial cell growth factor (VEGF) receptor-2] was used to confirm the endothelial phenotype.
Results:
Cancer patients with progressive disease (95 patients) had on average 3.6-fold more CECs than healthy subjects (46 patients, P <0.001). Patients (17) with stable disease had CEC numbers equal to that circulating in healthy subjects (P = 0.69). A subset of in vitro cultured CECs incorporated into endothelial layers and formed colonies. Plasma levels of cytokines that are thought to mobilize CECs from the bone marrow [VEGF, placental growth factor, stromal cell derived factor 1
and stem cell factor (71 patients)] did not correlate with CEC amounts. The levels of viable CECs in cancer patients were modified by granulocyte colony-stimulating factor treatment and chemotherapy.
Conclusion:
In progressive cancer patients, the amount of CECs is increased. These CECs are viable and may contribute to vessel formation. The number of CECs is influenced by anticancer treatment.
Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands
Key words: angiogenesis, cancer, circulating endothelial cells
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Taylor, J. Rossler, B. Geoerger, A. Laplanche, O. Hartmann, G. Vassal, and F. Farace High Levels of Circulating VEGFR2+ Bone Marrow-Derived Progenitor Cells Correlate with Metastatic Disease in Patients with Pediatric Solid Malignancies Clin. Cancer Res., July 15, 2009; 15(14): 4561 - 4571. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-J. Kim, J.-S. Kim, J. Papadopoulos, S. Wook Kim, M. Maya, F. Zhang, J. He, D. Fan, R. Langley, and I. J. Fidler Circulating Monocytes Expressing CD31: Implications for Acute and Chronic Angiogenesis Am. J. Pathol., May 1, 2009; 174(5): 1972 - 1980. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Campioni, A. L. Monaco, F. Lanza, S. Moretti, L. Ferrari, M. Fotinidi, R. La Corte, A. Cuneo, and F. Trotta CXCR4pos circulating progenitor cells coexpressing monocytic and endothelial markers correlating with fibrotic clinical features are present in the peripheral blood of patients affected by systemic sclerosis Haematologica, August 1, 2008; 93(8): 1233 - 1237. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. J. Povsic and P. J. Goldschmidt-Clermont Review: Endothelial progenitor cells: markers of vascular reparative capacity Therapeutic Advances in Cardiovascular Disease, June 1, 2008; 2(3): 199 - 213. [Abstract] [PDF]
|
|
|
|
|
|
J. M. Rademaker-Lakhai, L. V. Beerepoot, N. Mehra, S. A. Radema, R. van Maanen, J. S. Vermaat, E. O. Witteveen, C. M. Visseren-Grul, L. Musib, N. Enas, et al. Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Protein Kinase C {beta}-Inhibitor Enzastaurin in Combination with Gemcitabine and Cisplatin in Patients with Advanced Cancer Clin. Cancer Res., August 1, 2007; 13(15): 4474 - 4481. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Norden-Zfoni, J. Desai, J. Manola, P. Beaudry, J. Force, R. Maki, J. Folkman, C. Bello, C. Baum, S. E. DePrimo, et al. Blood-Based Biomarkers of SU11248 Activity and Clinical Outcome in Patients with Metastatic Imatinib-Resistant Gastrointestinal Stromal Tumor Clin. Cancer Res., May 1, 2007; 13(9): 2643 - 2650. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Bhatt, P. Seth, and V. P. Sukhatme Biomarkers for Monitoring Antiangiogenic Therapy Clin. Cancer Res., January 15, 2007; 13(2): 777s - 780s. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Boos, G. Y.H. Lip, and A. D. Blann Circulating Endothelial Cells in Cardiovascular Disease J. Am. Coll. Cardiol., October 17, 2006; 48(8): 1538 - 1547. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J Heidemann, D G Binion, W Domschke, and T Kucharzik Antiangiogenic therapy in human gastrointestinal malignancies. Gut, October 1, 2006; 55(10): 1497 - 1511. [Full Text] [PDF]
|
|
|
|
 |
|
 L. V. Beerepoot, E. O. Witteveen, and E. E. Voest In Reply J. Clin. Oncol., August 20, 2006; 24(24): 4040a - 4041. [Full Text] [PDF]
|
|
|
|
|
|
N. Mehra, M. Penning, J. Maas, L. V. Beerepoot, N. van Daal, C. H. van Gils, R. H. Giles, and E. E. Voest Progenitor Marker CD133 mRNA Is Elevated in Peripheral Blood of Cancer Patients with Bone Metastases. Clin. Cancer Res., August 15, 2006; 12(16): 4859 - 4866. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. V. Beerepoot, S. A. Radema, E. O. Witteveen, T. Thomas, C. Wheeler, S. Kempin, and E. E. Voest Phase I Clinical Evaluation of Weekly Administration of the Novel Vascular-Targeting Agent, ZD6126, in Patients With Solid Tumors J. Clin. Oncol., April 1, 2006; 24(10): 1491 - 1498. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. G. Duda, K. S. Cohen, E. di Tomaso, P. Au, R. J. Klein, D. T. Scadden, C. G. Willett, and R. K. Jain Differential CD146 Expression on Circulating Versus Tissue Endothelial Cells in Rectal Cancer Patients: Implications for Circulating Endothelial and Progenitor Cells As Biomarkers for Antiangiogenic Therapy J. Clin. Oncol., March 20, 2006; 24(9): 1449 - 1453. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. Rigolin, C. Fraulini, M. Ciccone, E. Mauro, A. M. Bugli, C. De Angeli, M. Negrini, A. Cuneo, and G. Castoldi Neoplastic circulating endothelial cells in multiple myeloma with 13q14 deletion Blood, March 15, 2006; 107(6): 2531 - 2535. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Herbst, A. Onn, and A. Sandler Angiogenesis and Lung Cancer: Prognostic and Therapeutic Implications J. Clin. Oncol., May 10, 2005; 23(14): 3243 - 3256. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Beaudry, J. Force, G. N. Naumov, A. Wang, C. H. Baker, A. Ryan, S. Soker, B. E. Johnson, J. Folkman, and J. V. Heymach Differential Effects of Vascular Endothelial Growth Factor Receptor-2 Inhibitor ZD6474 on Circulating Endothelial Progenitors and Mature Circulating Endothelial Cells: Implications for Use as a Surrogate Marker of Antiangiogenic Activity Clin. Cancer Res., May 1, 2005; 11(9): 3514 - 3522. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Zhang, V. Vakil, M. Braunstein, E. L. P. Smith, J. Maroney, L. Chen, K. Dai, J. R. Berenson, M. M. Hussain, U. Klueppelberg, et al. Circulating endothelial progenitor cells in multiple myeloma: implications and significance Blood, April 15, 2005; 105(8): 3286 - 3294. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Abedin, Y. Tintut, and L. L. Demer Mesenchymal Stem Cells and the Artery Wall Circ. Res., October 1, 2004; 95(7): 671 - 676. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Rabascio, E. Muratori, P. Mancuso, A. Calleri, V. Raia, T. Foutz, S. Cinieri, G. Veronesi, G. Pruneri, P. Lampertico, et al. Assessing Tumor Angiogenesis: Increased Circulating VE-Cadherin RNA in Patients with Cancer Indicates Viability of Circulating Endothelial Cells Cancer Res., June 15, 2004; 64(12): 4373 - 4377. [Abstract] [Full Text] [PDF]
|
|